1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThese programs provide early-stage capital for innovative small U. S. companies to engage in federal Research & Development (R&D) with strong potential for commercialization, focusing on ophthalmology and vision sciences.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small U. S. companies. SBIR allows the small business to be the sole institution, while STTR requires a formal partnership with a university or other non-profit research institution. Confirm the full requirements in the official notice before applying.
The current listing shows phase I Feasibility grant: up to $323,090 (total costs) for 6 months to 2 years; Phase II R&D grant: up to $2,153,927 (total costs) for 2 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Small Business Innovative Research (SBIR) (R43/R44) and Small Business Technology Transfer Research (STTR) (R41/R42) programs is funded by National Eye Institute (NEI) / National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article